Loading...
Bilateral Trade Intelligence · $1.3M Total Trade · 30 Exporters · 30 Buyers · DGFT Verified · Updated March 2026
India exported $1.3M worth of pharmaceutical formulations to Gabon across 365 verified shipments, sourced from 30 Indian exporters supplying 30 Gabon buyers. The top exporters are AUROBINDO PHARMA LTD ($243.7K) and BIOLOGICAL E. LIMITED ($204.1K). The leading products are Ritonavir ($189K) and Darunavir ($100K). Average shipment value: $3.5K.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Lopinavir and Ritonavir Tablets 200 & 50mg 120's | $189.3K | 14.9% |
| 2 | Dtp-hepb-hib (pentavalent Vaccine) Fully | $142.8K | 11.3% |
| 3 | Darunavir 600mg Tablets (60's) (2376 Packs : 60's Bottle) | $99.9K | 7.9% |
| 4 | Abacavir and Lamivudine Tablets 600/300mg (9666 Packs) Batch No:bak72404a Mfg D… | $76.9K | 6.1% |
| 5 | Dtp-hepb-hib (pentavalent Vaccine) Fullyliquid Combination Vaccine 10 Dose Vial… | $47.8K | 3.8% |
| 6 | Lopinavir and Ritonavir Tablets 200 & 50mg 120's (2109 Pak) 253080 Ea | $37.9K | 3.0% |
| 7 | Tenofovir Disoproxil Fumarate 300mg + Lamivudine 300mg Tablets (30's) - No Cart… | $34.0K | 2.7% |
| 8 | Ritonavir 100mg Tablets (30's) - No Carton (4752 Packs : 30's Bottle) | $33.3K | 2.6% |
| 9 | Pharmaceuticals Formulations- Enoxaparinsodium Injection USP 40 MG in 0.4 ML (t… | $32.2K | 2.5% |
| 10 | Efavirenz/lamivudine/tenofovir 400/300/300mg Tablets(2636 Pack,size:1x90) (batc… | $31.1K | 2.5% |
| 11 | Efavirenz 400mg+lamivudine300mg+tenofovir Disoproxilfumarate 300mg Tablets (243… | $28.7K | 2.3% |
| 12 | Pharma Products(finished Product)atazorr 300/100mg Tablet 30s Wtc 2736 Pac(1x30 | $27.1K | 2.1% |
| 13 | 3.5% W/v Polygeline Colloidal Solution with Electrolytes (pentacil) Batch No.24… | $26.7K | 2.1% |
| 14 | Dtp Hepb Hib Pentavalent Vaccine Fullyliquid Combination Vaccine 10 Dose Vialpa… | $24.9K | 2.0% |
| 15 | Material Kit Accouchement As Per Invoice | $19.2K | 1.5% |
India exports 20+ pharmaceutical formulations to Gabon with a combined trade value of $1.3M. Key products include Ritonavir ($189K), Darunavir ($100K), Tenofovir ($34K), Efavirenz ($31K). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 365 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Gabon, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Gabon buyers, regulatory requirements, and logistics for that specific product corridor. Products include Ritonavir ($189K), Darunavir ($100K), Tenofovir ($34K), Efavirenz ($31K) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
Historical evolution, India's market position, and recent developments
The pharmaceutical trade between India and Gabon has experienced steady growth over the past decade. In 2024, India's pharmaceutical exports to Gabon were valued at $3.48 million, marking a significant increase from previous years. This upward trajectory reflects India's expanding presence in the African pharmaceutical market and Gabon's growing demand for quality medicines. The trade encompasses a diverse range of products, including antiretrovirals, vaccines, and other essential medicines, underscoring the strategic importance of this bilateral corridor.
India holds a substantial share of Gabon's pharmaceutical imports, positioning itself as a key supplier in the region. In 2024, pharmaceutical products accounted for $3.48 million of India's total exports to Gabon, indicating a strong market presence. This dominance is attributed to India's competitive pricing, adherence to international quality standards, and a comprehensive product portfolio that meets Gabon's healthcare needs.
Between 2024 and 2026, several developments have influenced the India-Gabon pharmaceutical trade. In February 2026, Gabon's National Agency for Medicines and Other Health Products (ANMAPS) initiated a national training program for pharmaceutical inspectors. This initiative aims to enhance regulatory compliance and quality standards across Gabon's medicine supply chain, potentially impacting the importation and distribution processes of pharmaceutical products.
30 Indian pharmaceutical companies export finished formulations to Gabon. Leading exporters include Aurobindo Pharma Ltd, Biological E. Limited, Mylan Laboratories Limited, Macleods Pharmaceuticals Ltd. The top exporter accounts for 19.2% of total India–Gabon pharma exports. Source: Indian Customs (DGFT).
30 companies in Gabon import pharmaceutical formulations from India. Top buyers include Office Pharmaceutique National, Company Ags For Program, President Of The Republic Of Gabon, Office Pharmaceutique Nationale Com. The largest buyer accounts for 48.2% of India–Gabon pharma imports. Source: Indian Customs (DGFT).
Registration process, GMP requirements, import documentation
Indian pharmaceutical companies seeking to register products in Gabon must comply with the requirements set by the National Drug Regulatory Authority, which adheres to WHO-GMP standards. The registration process involves submitting a comprehensive dossier, typically in the Common Technical Document (CTD) format, which includes detailed information on the product's quality, safety, and efficacy. Bioequivalence studies may be required for certain products, especially generics, to demonstrate therapeutic equivalence to the reference product. The timeline for registration can vary, but companies should anticipate a process that may take several months, depending on the complexity of the product and the completeness of the submitted documentation.
Gabon mandates that manufacturing facilities exporting pharmaceutical products to the country adhere to Good Manufacturing Practice (GMP) standards recognized by the World Health Organization. Indian manufacturers must ensure their facilities are compliant with these standards, which encompass aspects such as quality management systems, personnel qualifications, premises and equipment, documentation, production, and quality control. The inspection process involves a thorough evaluation of the facility's operations and documentation to verify compliance. While Gabon recognizes WHO-GMP certifications, manufacturers should be prepared for potential inspections by Gabonese authorities to confirm adherence to local regulations.
For pharmaceutical imports into Gabon, the following documentation is typically required:
Customs procedures for pharmaceutical imports into Gabon require these documents to be submitted for clearance. Additionally, a bill of lading and an invoice must accompany all goods entering Gabon. Import permits and sanitary certificates are required for farm produce, and permits must also be secured for hazardous products.
Dominant categories, emerging opportunities, and demand drivers
India's pharmaceutical exports to Gabon are predominantly in the categories of antiretrovirals and vaccines. These products align with Gabon's healthcare priorities, particularly in the management of HIV/AIDS and immunization programs. The demand for antiretrovirals is driven by the high prevalence of HIV in the region, while vaccines are essential for preventing infectious diseases. The therapeutic areas of antiretrovirals and vaccines dominate India's pharmaceutical exports to Gabon, reflecting the country's strategic focus on addressing Gabon's public health needs.
The evolving healthcare landscape in Gabon presents emerging opportunities for Indian pharmaceutical exporters. The global patent expirations, known as patent cliffs, are creating openings for generic versions of previously patented drugs, which Indian manufacturers can supply. Additionally, the increasing demand for biosimilars in Gabon offers a potential market for Indian companies with expertise in this area. Exploring new therapeutic areas, such as oncology and chronic diseases, could further diversify India's export portfolio to Gabon.
Gabon's disease burden, characterized by high rates of infectious diseases like malaria and HIV/AIDS, significantly drives the demand for pharmaceutical imports. The aging population is also contributing to an increased prevalence of chronic diseases, further elevating the need for a diverse range of medications. Healthcare spending trends indicate a growing investment in health infrastructure and services, which is expected to boost the importation of pharmaceutical products to meet the population's needs.
Tariff structure, trade agreements, IP and patent landscape
Gabon applies the Most Favored Nation (MFN) tariff rates to pharmaceutical imports, ensuring non-discriminatory treatment for all trading partners. While specific preferential rates or duty exemptions for pharmaceutical formulations are not detailed, Gabon does not require an import license for pharmaceutical products. However, a certificate of conformity is required for regulated goods, including pharmaceuticals.
Gabon is a member of the Central African Economic and Monetary Community (CEMAC), which aims to promote economic integration among member states. While there is no specific Free Trade Agreement (FTA) between India and Gabon, the CEMAC framework may influence trade policies and tariffs within the region. Current or upcoming negotiations could further impact pharmaceutical trade dynamics, and stakeholders should monitor developments in this area.
Gabon adheres to international intellectual property (IP) agreements, including the Trade-Related Aspects of Intellectual Property Rights (TRIPS) under the World Trade Organization. Patent provisions in Gabon provide protection for pharmaceutical innovations, which can affect the entry of generic drugs. Data exclusivity periods may also impact the availability of generic versions of certain medications. Compulsory licensing provisions exist but are typically invoked under specific circumstances, such as public health emergencies. Indian generic manufacturers should assess the IP landscape to navigate potential challenges in market entry.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical shipments from India to Gabon primarily utilize sea routes, with major ports including Sahar Air and JNPT/Nhava Sheva Sea in India, and Libreville in Gabon. Air freight is also utilized, especially for time-sensitive deliveries. Transit times vary depending on the mode of transport and specific logistics arrangements. Potential disruptions, such as geopolitical tensions or natural events affecting the Red Sea, can impact shipping routes and schedules, necessitating contingency planning.
In India, Sahar Air accounts for 41.9% of pharmaceutical exports, JNPT/Nhava Sheva Sea handles 1.9%, and Delhi Air manages 6.6%. In Gabon, Libreville is the primary import port, handling 87.9% of pharmaceutical imports, with Libreville accounting for an additional 1.9%. These ports are equipped to handle pharmaceutical shipments, but infrastructure capabilities and customs procedures may vary, affecting logistics efficiency.
Maintaining the integrity of the cold chain is critical for pharmaceutical products, especially vaccines and biologics. Logistics providers must ensure temperature-controlled environments throughout the shipping process, from storage in India to delivery in Gabon. Compliance with Good Distribution Practice (GDP) standards is essential to ensure product quality and safety. Packaging standards must also meet international guidelines to prevent damage and contamination during transit.
Market size, healthcare system, growth outlook
Gabon's pharmaceutical market is valued at approximately $110.95 million as of 2023, with a steady growth trajectory. The market is heavily import-dependent, with pharmaceutical imports significantly exceeding domestic production. Generics constitute a substantial portion of the market, driven by cost considerations and the availability of high-quality generic medicines from suppliers like India.
Gabon's government healthcare programs focus on improving access to essential medicines, particularly for infectious diseases and chronic conditions. Insurance coverage is expanding, increasing the population's ability to afford medications. The drug procurement system is centralized, with the Ministry of Health overseeing the importation and distribution of pharmaceuticals, ensuring quality control and equitable access.
Indian pharmaceutical exporters have significant opportunities in Gabon, particularly in supplying antiretrovirals, vaccines, and other essential medicines. The growing demand for generics presents a favorable
India exported pharmaceuticals worth $1.3M to Gabon across 365 verified shipments.
1. AUROBINDO PHARMA LTD — $243.7K. 2. BIOLOGICAL E. LIMITED — $204.1K. 3. MYLAN LABORATORIES LIMITED — $200.5K. Total: 30 suppliers.
1. OFFICE PHARMACEUTIQUE NATIONAL — $610.5K. 2. COMPANY AGS FOR PROGRAM — $204.1K. 3. PRESIDENT OF THE REPUBLIC OF GABON — $99.1K. 30 buyers total.
1. Lopinavir and Ritonavir Tablets 200 & 50mg 120's ($189.3K, 14.9%); 2. Dtp-hepb-hib (pentavalent Vaccine) Fully ($142.8K, 11.3%); 3. Darunavir 600mg Tablets (60's) (2376 Packs : 60's Bottle) ($99.9K, 7.9%); 4. Abacavir and Lamivudine Tablets 600/300mg (9666 Packs) Batch No:bak72404a Mfg D… ($76.9K, 6.1%); 5. Dtp-hepb-hib (pentavalent Vaccine) Fullyliquid Combination Vaccine 10 Dose Vial… ($47.8K, 3.8%)
Export: SAHAR AIR, JNPT/ NHAVA SHEVA SEA, DELHI AIR, HYDERABAD ACC (INHYD4), SAHAR AIR CARGO ACC (INBOM4). Import: LIBREVILLE, Libreville.
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $1.3M corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$3.5K per consignment across 365 shipments.
30 Indian companies. Largest: AUROBINDO PHARMA LTD with $243.7K.
TransData Nexus covers 30 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 365 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
30 Exporters
30 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists